#Healthcareproviders: Did you know that every patient with non-small cell #lungcancer has their own unique set of biomarkers? Knowing their #biomarkers can indicate treatment options and is a crucial step in their #NSCLC journey. Visit the #NoOneMissed website to learn more about comprehensive #biomarker testing and how it may help you determine the right care plan for your patients: no1missed.org/3PyYkOm
LUNGevity Foundation’s Post
More Relevant Posts
-
#Healthcareproviders: have you tested your non-small cell #lungcancer patients for all clinically recommended biomarkers? Explore our #NoOneMissed page created for providers to find a discussion guide to help you start a conversation with your patients on what #biomarkertesting is, why it's crucial, and how it may be used to inform a treatment plan for their type of #NSCLC: no1missed.org/3QRu4Pc
-
Novel biomarkers and targeted therapies offer hope for early detection and tailored treatment. See more in detail: https://lnkd.in/dgJ2-NAz #BladderCancerResearch #cancerjournal #CancerResearch #EarlyDetection #GenomicBreakthrough #ImmunotherapyAdvances #medx #newpost #PersonalizedTreatment #reseapro #reseaprojournals #trending
-
-
In this #CME activity, expert faculty explores new efficacy & safety data on targeted therapies for #NSCLC. Learn which biomarkers are essential to test for before initiating treatment and the latest data on targeted first-line and second-line treatments. https://bit.ly/47VySZP
-
-
Register to join experts Amit Bar-or, MD, FRCPC, and Jiwon Oh, MD, PhD, FRCPC, on May 31 at 6:30 AM CDT during #CMSC2024 and better understand the current and future roles of novel biomarkers in #MultipleSclerosis (#MS) treatment! https://bit.ly/2024MSL #MedEd
-
Join us for #HTTR24 w/focus on a critical & timely theme: "Tolerance & Resistance to Targeted Therapy in NSCLC", diving deep into the mechanisms, biomarkers, & models that drive our understanding & treatment of drug tolerance & resistance in #NSCLC: https://bit.ly/HTTR24-Reg #LCSM
-
-
Register to join experts amit bar-or, MD, FRCPC, and Jiwon Oh, MD, PhD, FRCPC, on May 31 at 6:30 AM CDT during #CMSC2024 and better understand the current and future roles of novel biomarkers in #MultipleSclerosis (#MS) treatment! https://bit.ly/2024MSL #MedEd
-
Immunohistochemistry plays a critical role in the classification of tumors into subtypes and for assessing biomarkers for timely and accurate therapeutic decision. Agilus Diagnostics offers Custom IHC panel which provide final diagnosis to clinicians by expert team of oncopathologist using automated IHC platforms and wide array of IHC markers. #AgilusDiagnostics #lungcancerawarenessmonth
